A Phase 1b, Open-label, Parallel-group Study in Subjects With Huntington Disease to Assess the Safety, Tolerability, and Fed/Fasted Pharmacokinetics of Repeated Oral Doses of SEN0014196.
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Selisistat (Primary)
- Indications Huntington's disease
- Focus Biomarker; Pharmacokinetics
- 13 Nov 2012 Planned end date changed from 1 Aug 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
- 13 Nov 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 01 Jun 2012 Additional lead trial investigators identified as reported by ClinicalTrials.gov.